Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 623

1.

Lymphocyte innateness defined by transcriptional states reflects a balance between proliferation and effector functions.

Gutierrez-Arcelus M, Teslovich N, Mola AR, Polidoro RB, Nathan A, Kim H, Hannes S, Slowikowski K, Watts GFM, Korsunsky I, Brenner MB, Raychaudhuri S, Brennan PJ.

Nat Commun. 2019 Feb 8;10(1):687. doi: 10.1038/s41467-019-08604-4.

2.

PCSK9 inhibition 2018: riding a new wave of coronary prevention.

Ward NC, Page MM, Watts GF.

Clin Sci (Lond). 2019 Jan 22;133(2):205-224. doi: 10.1042/CS20171300. Print 2019 Jan 31. Review.

PMID:
30670671
3.

Effect of Statin Therapy on Arterial Wall Inflammation Based on 18F-FDG PET/CT: A Systematic Review and Meta-Analysis of Interventional Studies.

Pirro M, Simental-Mendía LE, Bianconi V, Watts GF, Banach M, Sahebkar A.

J Clin Med. 2019 Jan 18;8(1). pii: E118. doi: 10.3390/jcm8010118. Review.

4.

Statin Toxicity.

Ward NC, Watts GF, Eckel RH.

Circ Res. 2019 Jan 18;124(2):328-350. doi: 10.1161/CIRCRESAHA.118.312782.

PMID:
30653440
5.

Editorial: Familial Hypercholesterolaemia Registry in the MENA Region

Kolovou G, Watts GF.

Curr Vasc Pharmacol. 2019 Jan 16:1. [Epub ahead of print] No abstract available.

PMID:
30650941
6.

Simon Broome confirms that the IAS definition of severe familial hypercholesterolemia predicts coronary mortality in patients with FH.

Santos RD, Watts GF.

Atherosclerosis. 2018 Dec 22. pii: S0021-9150(18)31544-2. doi: 10.1016/j.atherosclerosis.2018.12.013. [Epub ahead of print] No abstract available.

PMID:
30642653
7.

Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia.

Vuorio A, Watts GF, Kovanen PT.

Atherosclerosis. 2018 Dec 7;281:25-30. doi: 10.1016/j.atherosclerosis.2018.11.040. [Epub ahead of print] Review.

PMID:
30616181
8.

Patients with type 1 diabetes in a tertiary setting do not attain recommended lipid targets.

Lan NSR, Yeap BB, Bell DA, Watts GF, Gerry Fegan P.

Diabetes Metab. 2019 Jan 1. pii: S1262-3636(18)30223-4. doi: 10.1016/j.diabet.2018.12.002. [Epub ahead of print] No abstract available.

PMID:
30609387
9.

Improving the detection of familial hypercholesterolaemia.

Lan NSR, Martin AC, Brett T, Watts GF, Bell DA.

Pathology. 2019 Feb;51(2):213-221. doi: 10.1016/j.pathol.2018.10.015. Epub 2018 Dec 19. Review.

PMID:
30579649
10.

Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials.

Sahebkar A, Simental-Mendía LE, Pirro M, Banach M, Watts GF, Sirotri C, Al-Rasadi K, Atkin SL.

Sci Rep. 2018 Dec 14;8(1):17887. doi: 10.1038/s41598-018-36204-7.

11.

Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.

Ma L, Waldmann E, Ooi EMM, Chan DC, Barrett HPR, Watts GF, Parhofer KG.

Eur J Clin Invest. 2019 Feb;49(2):e13053. doi: 10.1111/eci.13053. Epub 2018 Dec 13.

PMID:
30447089
12.

Dyslipidaemia in adults with type 1 diabetes-when to treat?

Lan NSR, Fegan PG, Yeap BB, Bell DA, Watts GF.

Diabetes Metab Res Rev. 2019 Jan;35(1):e3090. doi: 10.1002/dmrr.3090. Epub 2018 Nov 8.

PMID:
30339719
13.

Writing on the wall for precision medicine in the prevention of atherosclerotic cardiovascular disease.

Watts GF, Stroes ESG.

Curr Opin Lipidol. 2018 Dec;29(6):433-435. doi: 10.1097/MOL.0000000000000560. No abstract available.

PMID:
30325759
14.

Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal.

Boffa MB, Stranges S, Klar N, Moriarty PM, Watts GF, Koschinsky ML.

J Clin Lipidol. 2018 Nov - Dec;12(6):1358-1366. doi: 10.1016/j.jacl.2018.08.012. Epub 2018 Sep 11. Review.

PMID:
30316749
15.

Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions.

Penson PE, Mancini GBJ, Toth PP, Martin SS, Watts GF, Sahebkar A, Mikhailidis DP, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration (LBPMC) Group & International Lipid Expert Panel (ILEP).

J Cachexia Sarcopenia Muscle. 2018 Dec;9(6):1023-1033. doi: 10.1002/jcsm.12344. Epub 2018 Oct 11.

16.

Lipoprotein(a): lodestar for future clinical trials.

Watts GF, Boffa MB.

Lancet. 2018 Oct 13;392(10155):1281-1282. doi: 10.1016/S0140-6736(18)31922-6. Epub 2018 Oct 4. No abstract available.

PMID:
30293767
17.

Knowledge, awareness and practice regarding familial hypercholesterolaemia among primary care physicians in Malaysia: The importance of professional training.

Azraii AB, Ramli AS, Ismail Z, Abdul-Razak S, Mohd-Kasim NA, Ali N, Watts GF, Nawawi H.

Atherosclerosis. 2018 Oct;277:508-516. doi: 10.1016/j.atherosclerosis.2018.08.018.

PMID:
30270092
18.

Effects of medication, treatment, and behavioral beliefs on intentions to take medication in patients with familial hypercholesterolemia.

Hagger MS, Hardcastle SJ, Hu M, Kwok S, Lin J, Nawawi HM, Pang J, Santos RD, Soran H, Su TC, Tomlinson B, Watts GF.

Atherosclerosis. 2018 Oct;277:493-501. doi: 10.1016/j.atherosclerosis.2018.06.010.

PMID:
30270090
19.

Heterozygous familial hypercholesterolaemia in specialist centres in South Africa, Australia and Brazil: Importance of early detection and lifestyle advice.

Pang J, David Marais A, Blom DJ, Brice BC, Silva PR, Jannes CE, Pereira AC, Hooper AJ, Ray KK, Santos RD, Watts GF.

Atherosclerosis. 2018 Oct;277:470-476. doi: 10.1016/j.atherosclerosis.2018.06.822.

PMID:
30270087
20.

Screening for familial hypercholesterolaemia in primary care: Time for general practice to play its part.

Brett T, Qureshi N, Gidding S, Watts GF.

Atherosclerosis. 2018 Oct;277:399-406. doi: 10.1016/j.atherosclerosis.2018.08.019. Review.

PMID:
30270077
21.

Homozygous familial hypercholesterolaemia in Vietnam: Case series, genetics and cascade testing of families.

Truong TH, Kim NT, Nguyen MNT, Pang J, Hooper AJ, Watts GF, Do DL.

Atherosclerosis. 2018 Oct;277:392-398. doi: 10.1016/j.atherosclerosis.2018.06.013.

PMID:
30270076
22.

Improving the global care of familial hypercholesterolaemia: Starting the ball rolling.

Ray KK, Watts GF.

Atherosclerosis. 2018 Oct;277:230-233. doi: 10.1016/j.atherosclerosis.2018.09.002. No abstract available.

PMID:
30270053
23.

MicroRNAs: Novel Molecular Targets and Response Modulators of Statin Therapy.

Mohajeri M, Banach M, Atkin SL, Butler AE, Ruscica M, Watts GF, Sahebkar A.

Trends Pharmacol Sci. 2018 Nov;39(11):967-981. doi: 10.1016/j.tips.2018.09.005. Epub 2018 Sep 21. Review.

PMID:
30249403
24.

Loneliness in psychotic illness and its association with cardiometabolic disorders.

Badcock JC, Mackinnon A, Waterreus A, Watts GF, Castle D, McGrath JJ, Morgan VA.

Schizophr Res. 2018 Sep 19. pii: S0920-9964(18)30579-6. doi: 10.1016/j.schres.2018.09.021. [Epub ahead of print]

PMID:
30243852
25.

Association between phenotypic familial hypercholesterolaemia and telomere length in US adults: results from a multi-ethnic survey.

Banach M, Mazidi M, Mikhailidis DP, Toth PP, Jozwiak J, Rysz J, Watts GF.

Eur Heart J. 2018 Oct 21;39(40):3635-3640. doi: 10.1093/eurheartj/ehy527.

PMID:
30165413
26.

Simplified Canadian Definition for Familial Hypercholesterolemia.

Ruel I, Brisson D, Aljenedil S, Awan Z, Baass A, Bélanger A, Bergeron J, Bewick D, Brophy JM, Brunham LR, Couture P, Dufour R, Francis GA, Frohlich J, Gagné C, Gaudet D, Grégoire JC, Gupta M, Hegele RA, Mancini GBJ, McCrindle BW, Pang J, Raggi P, Tu JV, Watts GF, Genest J.

Can J Cardiol. 2018 Sep;34(9):1210-1214. doi: 10.1016/j.cjca.2018.05.015. Epub 2018 May 19.

27.

In search of the vulnerable patient or the vulnerable plaque: 18F-sodium fluoride positron emission tomography for cardiovascular risk stratification.

Bellinge JW, Francis RJ, Majeed K, Watts GF, Schultz CJ.

J Nucl Cardiol. 2018 Oct;25(5):1774-1783. doi: 10.1007/s12350-018-1360-2. Epub 2018 Jul 10.

PMID:
29992525
28.

Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque.

Ooi EM, Ellis KL, Barrett PHR, Watts GF, Hung J, Beilby JP, Thompson PL, Stobie P, McQuillan BM.

Atherosclerosis. 2018 Aug;275:232-238. doi: 10.1016/j.atherosclerosis.2018.06.863. Epub 2018 Jun 18.

PMID:
29960898
29.

The Role of Nutraceuticals in Statin Intolerant Patients.

Banach M, Patti AM, Giglio RV, Cicero AFG, Atanasov AG, Bajraktari G, Bruckert E, Descamps O, Djuric DM, Ezhov M, Fras Z, von Haehling S, Katsiki N, Langlois M, Latkovskis G, Mancini GBJ, Mikhailidis DP, Mitchenko O, Moriarty PM, Muntner P, Nikolic D, Panagiotakos DB, Paragh G, Paulweber B, Pella D, Pitsavos C, Reiner Ž, Rosano GMC, Rosenson RS, Rysz J, Sahebkar A, Serban MC, Vinereanu D, Vrablík M, Watts GF, Wong ND, Rizzo M; International Lipid Expert Panel (ILEP).

J Am Coll Cardiol. 2018 Jul 3;72(1):96-118. doi: 10.1016/j.jacc.2018.04.040. Review.

PMID:
29957236
30.

PCSK9 monoclonal antibody on a knife-edge: An article of faith in FH?

Ward NC, Watts GF.

J Clin Lipidol. 2018 Jul - Aug;12(4):844-848. doi: 10.1016/j.jacl.2018.05.015. Epub 2018 Jun 1. No abstract available.

PMID:
29945779
31.

Squaring up the health economics of PCSK9 monoclonal antibodies 'down under'.

Watts GF, Norman R.

Int J Cardiol. 2018 Sep 15;267:193-194. doi: 10.1016/j.ijcard.2018.06.003. Epub 2018 Jun 2. No abstract available.

PMID:
29887280
32.

Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism.

Chan DC, Watts GF, Somaratne R, Wasserman SM, Scott R, Barrett PHR.

Arterioscler Thromb Vasc Biol. 2018 Jul;38(7):1644-1655. doi: 10.1161/ATVBAHA.118.310882. Epub 2018 Jun 7.

33.

The Present and the Future of Genetic Testing in Familial Hypercholesterolemia: Opportunities and Caveats.

Hooper AJ, Burnett JR, Bell DA, Watts GF.

Curr Atheroscler Rep. 2018 May 19;20(6):31. doi: 10.1007/s11883-018-0731-0. Review.

PMID:
29779130
34.

Fenofibrate effects on carotid artery intima-media thickness in adults with type 2 diabetes mellitus: A FIELD substudy.

Harmer JA, Keech AC, Veillard AS, Skilton MR, Watts GF, Celermajer DS; FIELD Vascular Study Investigators.

Diabetes Res Clin Pract. 2018 Jul;141:156-167. doi: 10.1016/j.diabres.2018.05.006. Epub 2018 May 26.

PMID:
29763709
35.

Quantifying Atherogenic Lipoproteins: Current and Future Challenges in the Era of Personalized Medicine and Very Low Concentrations of LDL Cholesterol. A Consensus Statement from EAS and EFLM.

Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, Watts GF, Borén J, Baum H, Bruckert E, Catapano A, Descamps OS, von Eckardstein A, Kamstrup PR, Kolovou G, Kronenberg F, Langsted A, Pulkki K, Rifai N, Sypniewska G, Wiklund O, Nordestgaard BG; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative.

Clin Chem. 2018 Jul;64(7):1006-1033. doi: 10.1373/clinchem.2018.287037. Epub 2018 May 14.

PMID:
29760220
36.

Rationale and design of a trial to personalize risk assessment in familial coronary artery disease.

Marwick TH, Whitmore K, Nicholls SJ, Stanton T, Mitchell G, Tonkin A, Blizzard C, Neil A, Jones C, Watts GF; CAUGHT-CAD Investigators.

Am Heart J. 2018 May;199:22-30. doi: 10.1016/j.ahj.2017.09.011. Epub 2017 Sep 19.

PMID:
29754662
37.

Elevated lipoprotein(a) and low-density lipoprotein cholesterol as predictors of the severity and complexity of angiographic lesions in patients with premature coronary artery disease.

Chieng D, Pang J, Ellis KL, Hillis GS, Watts GF, Schultz CJ.

J Clin Lipidol. 2018 Jul - Aug;12(4):1019-1026. doi: 10.1016/j.jacl.2018.03.090. Epub 2018 Apr 3.

PMID:
29703625
38.

Parent-child genetic testing for familial hypercholesterolaemia in an Australian context.

Pang J, Martin AC, Bates TR, Hooper AJ, Bell DA, Burnett JR, Norman R, Watts GF.

J Paediatr Child Health. 2018 Jul;54(7):741-747. doi: 10.1111/jpc.13898. Epub 2018 Apr 6.

PMID:
29626384
39.

Is Lipoprotein(a) Ready for Prime-Time Use in the Clinic?

Ellis KL, Watts GF.

Cardiol Clin. 2018 May;36(2):287-298. doi: 10.1016/j.ccl.2017.12.010. Review.

PMID:
29609758
40.

Health literacy in familial hypercholesterolemia: A cross-national study.

Hagger MS, Hardcastle SJ, Hu M, Kwok S, Lin J, Nawawi HM, Pang J, Santos RD, Soran H, Su TC, Tomlinson B, Watts GF.

Eur J Prev Cardiol. 2018 Jun;25(9):936-943. doi: 10.1177/2047487318766954. Epub 2018 Mar 29.

PMID:
29592531
41.

The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease.

Barden AE, Shinde S, Burke V, Puddey IB, Beilin LJ, Irish AB, Watts GF, Mori TA.

Prostaglandins Other Lipid Mediat. 2018 May;136:1-8. doi: 10.1016/j.prostaglandins.2018.03.002. Epub 2018 Mar 22.

PMID:
29577973
42.

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics.

Watts GF, Chan DC, Somaratne R, Wasserman SM, Scott R, Marcovina SM, Barrett PHR.

Eur Heart J. 2018 Jul 14;39(27):2577-2585. doi: 10.1093/eurheartj/ehy122.

PMID:
29566128
43.

Elevated lipoprotein(a) and familial hypercholesterolemia in the coronary care unit: Between Scylla and Charybdis.

Ellis KL, Pang J, Chieng D, Bell DA, Burnett JR, Schultz CJ, Hillis GS, Watts GF.

Clin Cardiol. 2018 Mar;41(3):378-384. doi: 10.1002/clc.22880. Epub 2018 Feb 26.

44.

A Comparative Analysis of Phenotypic Predictors of Mutations in Familial Hypercholesterolemia.

Chan DC, Pang J, Hooper AJ, Bell DA, Bates TR, Burnett JR, Watts GF.

J Clin Endocrinol Metab. 2018 Apr 1;103(4):1704-1714. doi: 10.1210/jc.2017-02622.

PMID:
29408959
45.

Nutraceuticals in the management of patients with statin-associated muscle symptoms, with a note on real-world experience.

Ward NC, Pang J, Ryan JDM, Watts GF.

Clin Cardiol. 2018 Jan;41(1):159-165. doi: 10.1002/clc.22862. Epub 2018 Jan 24. Review.

46.

The impact of non-vitamin K antagonist oral anticoagulants (NOACs) on anticoagulation therapy in rural Australia.

Bellinge JW, Paul JJ, Walsh LS, Garg L, Watts GF, Schultz C.

Med J Aust. 2018 Jan 15;208(1):18-23.

PMID:
29320668
47.

Acute Impact of Different Exercise Modalities on Arterial and Platelet Function.

Haynes A, Linden MD, Robey E, Watts GF, Barrett PHR, Naylor LH, Green DJ.

Med Sci Sports Exerc. 2018 Apr;50(4):785-791. doi: 10.1249/MSS.0000000000001505.

PMID:
29240651
48.

Reverse cascade screening for familial hypercholesterolemia in high-risk Chinese families.

Wu X, Pang J, Wang X, Peng J, Chen Y, Wang S, Watts GF, Lin J.

Clin Cardiol. 2017 Nov;40(11):1169-1173. doi: 10.1002/clc.22809. Epub 2017 Nov 23.

49.

Effects of Allopurinol on Endothelial Function: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.

Cicero AFG, Pirro M, Watts GF, Mikhailidis DP, Banach M, Sahebkar A.

Drugs. 2018 Jan;78(1):99-109. doi: 10.1007/s40265-017-0839-5. Review.

PMID:
29139092
50.

Lipoprotein apheresis downregulates IL-1α, IL-6 and TNF-α mRNA expression in severe dyslipidaemia.

Stefanutti C, Mazza F, Pasqualetti D, Di Giacomo S, Watts GF, Massari MS, de Neve J, Morozzi C, Fischer M.

Atheroscler Suppl. 2017 Nov;30:200-208. doi: 10.1016/j.atherosclerosissup.2017.05.028.

PMID:
29096839

Supplemental Content

Loading ...
Support Center